Micah Benson

Company: KSQ Therapeutics

Job title: Chief Scientific Officer

Bio:

Micah Benson joined KSQ at its founding and was responsible for building KSQ’s Immuno-Oncology and Autoimmunity efforts, leading to a clinical-stage portfolio of multiple first-in-class therapeutics. A co-inventor of KSQ’s foundational Immune CRISPRomics® platform, Micah’s work led to the discovery of SOCS1 and Regnase-1 and the development of KSQ’s eTIL® programs, including KSQ-001EX and KSQ-004EX, as well as a broad strategic partnership established with Takeda to develop and commercialize novel Immuno-Oncology therapeutics. Prior to joining KSQ, Micah served as the Head of Tolerance Therapeutics in the Immunology and Inflammation Research Unit at Pfizer, Inc., where he was responsible for building and leading a drug discovery portfolio and identifying external research opportunities focused on immune tolerance induction therapeutics. He earned his PhD in Immunology from Dartmouth Medical School where his work on B cell survival and T regulatory cell differentiation generated fundamental insights into the mechanisms of immune-mediated diseases. Micah subsequently served as a Leukemia Lymphoma Society fellow at Harvard Medical School where he studied mRNA splicing in B lymphocyte differentiation. He is the author of several patents and multiple publications in top-tier scientific journals.

Seminars:

Driving Innovation in TIL Therapy with a Pipeline Update from KSQ Therapeutics 9:10 am

Showcasing recent clinical data on the efficacy and safety of KSQ Therapeutics’ engineered TIL therapies across multiple cancer types Exploring how gene-editing strategies are improving TIL function and persistence, with implications for more durable and effective patient outcomesRead more

day: Conference Day One AM

Fireside Chat: Clinical Data & Reflections on the Current State of TIL Therapies in the Clinic 9:30 am

Examining the latest clinical insights shaping TIL therapy to better understand the direction of innovation in the field Discussing real-world challenges and opportunities in TIL development to uncover practical strategies for accelerating progress Envisioning the future of TIL therapies through expert perspectives to inform more effective research and clinical decisionsRead more

day: Conference Day One AM